10x Genomics, Inc. — Form 8-K Summary
Business context and reporting period
10x Genomics filed a current report on December 11, 2019, reporting a change in its board composition. The company is an emerging growth company, and its Class A common stock trades on Nasdaq under the symbol TXG.
Board resignation
Paul A. Conley resigned, effective immediately, from the company’s Board of Directors and its Nominating and Corporate Governance Committee.
The filing states that the resignation resulted solely from time commitments and Mr. Conley’s personal decision to pursue other business opportunities. It was not due to any disagreement with management, operations, financial statements, policies, or procedures.
Financial metrics and liquidity
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial metrics.
Material changes, outlook, and risks
The reported change is limited to the resignation of one director and committee member. The filing does not disclose revised guidance, management outlook, contingencies, unusual financial items, or additional risks.
Key facts to verify
- Confirm the effective date of Mr. Conley’s resignation: December 11, 2019.
- Confirm that the resignation was stated to be unrelated to any disagreement with the company.
- Review subsequent filings for changes to board composition, committee membership, or replacement director appointments.